Trulieve Reports Third Quarter Revenues of US$70.7 Million

Trulieve Cannabis Corp (CSE: TRUL) announced its third quarter financial results after the bell today, reporting revenues of US$70.7 million for the period ended September 30, 2019. Revenues were up 22% on a quarter over quarter basis from $57.9 million.

Gross margin for the quarter came in at $44.0 million before biological adjustments, up 17% on a sequential basis, which translates to a 62% gross margin for the period. Total expenses came in at $20.6 million, with sales and marketing accounting for the largest portion at $14.7 million. General and administrative expenses totaled $3.2 million during the quarter.

Thanks in part to a $89.0 million bump from biological adjustments, Trulieve managed to post a net income of $60.2 million for the three month period ended September 30. However, even without this adjustment the firm would have posted a positive net income quarter, which is rare within the cannabis space.

In terms of cash flow, the quarter saw negative cash flow from its operating expenditures of $3.3 million. Capital expenditures also contributed to a negative cash flow quarter, with $18.4 million spent during the quarter cumulative on investing activities. Total cash decreased during the quarter, from $54.0 million to $31.0 million.

Trulieve’s inventories climbed significantly during the quarter, growing from $85.2 million to $144.3 million, while biological assets climbed from $49.4 million to $62.4 million. Total current assets grew during the quarter from $192.4 million to $242.3 million. Meanwhile, current liabilities decreased from $63.2 million to $49.0 million. Total working capital during the quarter grew to $193.2 million.

Trulieve reaffirmed its prior outlook for 2019, guiding towards $220 million to $240 million in revenues for 2019, and between $380 million and $400 million for 2020. Adjusted EBITDA for the current fiscal year is expected to be between $95 to $105 million.

Trulieve has revenued $173.1 million for the nine month period ending September 30, 2019.

Trulieve closed today’s session at $14.95 on the CSE.


Information for this briefing was found via Sedar and Trulieve. The author holds no securities of the organization discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Trulieve Loses Foreign Private Issuer Status, Must Transition To US GAAP Reporting Standards

Evidently, recent buying activity in Trulieve Cannabis Corp (CSE: TRUL) has come largely from South...

Tuesday, July 14, 2020, 09:16:53 AM

Trulieve, Harvest Health Receive Court Approval For Merger, Closing Timeline Remains Vague

Approval from the courts has been granted to Harvest Health (CSE: HARV) in relation to...

Thursday, August 19, 2021, 08:59:38 AM

Trulieve: Canaccord Reiterates $97 Price Target After Results

On November 15th, Trulieve Cannabis (CSE: TRUL) reported its third quarter results, announcing record revenues...

Friday, November 19, 2021, 10:31:00 AM

US Cannabis: Stifel Expects Growth To Decelerate In Q4 Earnings

On February 2nd, Stifel-GMP put out their fourth quarter 2021 earnings preview, calling it “The...

Wednesday, February 9, 2022, 04:33:00 PM

Trulieve Cannabis: Analyst Q1 Consensus Estimates

Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their first quarter financials before...

Wednesday, May 12, 2021, 04:01:00 PM